tbuckley/cabot-search huggingface dataset:
Abstract 2917: Inhibition of Annexin A6 sensitizes triple negative breast cancer cells to radiation
Authors: Gladys N. Nangami, Amos Sakwe, Josiah Ochieng
Journal: Cancer Research (2019)

Abstract Introduction: Despite vast evidence that tumor genetics play a dominant role in determining radiosensitivity and ultimate benefit from radiation therapy (RT), current RT delivery algorithms have not successfully incorporated tumor biology. Instead, clinical decisions regarding the use of RT are still based on features of tumor aggressiveness such as stage, grade, degree of metastasis and type of surgery. We provide evidence showing that most aggressive basal-like TNBC cells characteristically expresses low levels of the Ca2+-dependent membrane-binding tumor suppressor Annexin A6 (AnxA6) as compared to mesenchymal-like TNBC cell lines. We have also shown that depletion of AnxA6 in TNBC cells induced severe morphological changes from the slow growing mesenchymal-like to rapidly growing basal-like phenotypes and that this was not only associated with enhanced anchorage independent cell proliferation, but significantly inhibited cell adhesion, motility and invasiveness. Given that rapidly proliferating cells are more radiosensitive, we hypothesized that the expression status of AnxA6 in triple negative breast cancer cells underlies their response to RT. Materials and Methods: For clonogenic assay, cells were grown to 70-80% confluency then were allowed to settle and attach for 8 hours before being exposed to irradiation at various doses. Dishes were then incubated at 37oC in 5% CO2 in a humidified incubator to form colonies for 14 days. Colonies (50 cells or more) were stained with crystal violet and enumerated under a Fisher Stereomaster II 10X stereoscopic microscope. Radiation induced cell cycle arrest was assessed by flow cytometry. Results: Our studies show that depletion of AnxA6, significantly increased the sensitivity of triple negative breast cancer cells via up-regulation of cell cycle pathways as demonstrated by lack of G2/M cell cycle arrest in cells with low level of AnxA6. Additionally, we demonstrate that knockdown of AnxA6 enhanced radiation induced DNA damage. Conclusions: Our findings demonstrate that reduced expression of AnxA6 enhances radiation sensitivity of triple negative breast cancer cells. Note: This abstract was not presented at the meeting. Citation Format: Gladys N. Nangami, Amos Sakwe, Josiah Ochieng. Inhibition of Annexin A6 sensitizes triple negative breast cancer cells to radiation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2917.
Are medical education and research being overfunded?
Authors: M. B. Visscher
Journal: JAMA (1971)

<h3>To the Editor.—</h3> In a time of economic stringency public fiscal officers look for ways of saving money without causing too much public dissatisfaction or too many political problems. With the retirement of Sen Lister Hill and the death of Cong John Fogarty, the political hazard to the White House in reducing funding for medical research and education was greatly diminished. It is probably no accident that the serious setback to federal funding of these enterprises occurred at the time that those powerful protagonists for medical research and education were lost to the cause. The void that was created points up the need for greater public understanding of the proper and necessary role of research and education in the delivery of health care and in future improvements in such care to the public interest. In fact, there is even need for better understanding by a minority of the medical profession
Harry Angelman Shevan AbdulKarim Ayoub Walter Calvert Sheila Mary Ross Dronfield (nee Williams) Jean Lilian Hallum Edward Harford-Rees Frank Edward Hobbs Air Vice Marshall Thomas ("Tom") Conchar Macdonald Thomas Goronwy Owen Alex Norman Barron Stott Basil Strickland Jennifer Ann Thomson (nee Chown)
Journal: BMJ (1997)
URIC ACID AND DERMATOSES
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation
Authors: Ingrid E Christophersen, Michiel Rienstra, Carolina Roselli, Xiaoyan Yin, Bastiaan Geelhoed, John Barnard, Honghuang Lin, Dan E Arking, Albert V Smith, Christine M Albert, Mark Chaffin, Nathan R Tucker, Molong Li, Derek Klarin, Nathan A Bihlmeyer, Siew-Kee Low, Peter E Weeke, Martina Müller-Nurasyid, J Gustav Smith, Jennifer A Brody, Maartje N Niemeijer, Marcus Dörr, Stella Trompet, Jennifer Huffman, Stefan Gustafsson, Claudia Schurmann, Marcus E Kleber, Leo-Pekka Lyytikäinen, Ilkka Seppälä, Rainer Malik, Andrea R V R Horimoto, Marco Perez, Juha Sinisalo, Stefanie Aeschbacher, Sébastien Thériault, Jie Yao, Farid Radmanesh, Stefan Weiss, Alexander Teumer, Seung Hoan Choi, Lu-Chen Weng, Sebastian Clauss, Rajat Deo, Daniel J Rader, Svati H Shah, Albert Sun, Jemma C Hopewell, Stephanie Debette, Ganesh Chauhan, Qiong Yang, Bradford B Worrall, Guillaume Paré, Yoichiro Kamatani, Yanick P Hagemeijer, Niek Verweij, Joylene E Siland, Michiaki Kubo, Jonathan D Smith, David R Van Wagoner, Joshua C Bis, Siegfried Perz, Bruce M Psaty, Paul M Ridker, Jared W Magnani, Tamara B Harris, Lenore J Launer, M Benjamin Shoemaker, Sandosh Padmanabhan, Jeffrey Haessler, Traci M Bartz, Melanie Waldenberger, Peter Lichtner, Marina Arendt, Jose E Krieger, Mika Kähönen, Lorenz Risch, Alfredo J Mansur, Annette Peters, Blair H Smith, Lars Lind, Stuart A Scott, Yingchang Lu, Erwin B Bottinger, Jussi Hernesniemi, Cecilia M Lindgren, Jorge A Wong, Jie Huang, Markku Eskola, Andrew P Morris, Ian Ford, Alex P Reiner, Graciela Delgado, Lin Y Chen, Yii-Der Ida Chen, Roopinder K Sandhu, Man Li, Eric Boerwinkle, Lewin Eisele, Lars Lannfelt, Natalia Rost, Christopher D Anderson, Kent D Taylor, Archie Campbell, Patrik K Magnusson, David Porteous, Lynne J Hocking, Efthymia Vlachopoulou, Nancy L Pedersen, Kjell Nikus, Marju Orho-Melander, Anders Hamsten, Jan Heeringa, Joshua C Denny, Jennifer Kriebel, Dawood Darbar, Christopher Newton-Cheh, Christian Shaffer, Peter W Macfarlane, Stefanie Heilmann-Heimbach, Peter Almgren, Paul L Huang, Nona Sotoodehnia, Elsayed Z Soliman, Andre G Uitterlinden, Albert Hofman, Oscar H Franco, Uwe Völker, Karl-Heinz Jöckel, Moritz F Sinner, Henry J Lin, Xiuqing Guo, Martin Dichgans, Erik Ingelsson, Charles Kooperberg, Olle Melander, Ruth J F Loos, Jari Laurikka, David Conen, Jonathan Rosand, Pim van der Harst, Marja-Liisa Lokki, Sekar Kathiresan, Alexandre Pereira, J Wouter Jukema, Caroline Hayward, Jerome I Rotter, Winfried März, Terho Lehtimäki, Bruno H Stricker, Mina K Chung, Stephan B Felix, Vilmundur Gudnason, Alvaro Alonso, Dan M Roden, Stefan Kääb, Daniel I Chasman, Susan R Heckbert, Emelia J Benjamin, Toshihiro Tanaka, Kathryn L Lunetta, Steven A Lubitz, Patrick T Ellinor
Journal: Nature Genetics (2017)
THE PREVENTION OF VENEREAL DISEASE
Authors: H. B. Donkin
Journal: BMJ (1922)

<b>Objective.</b> To produce, implement, and evaluate the effectiveness of a film to develop the foundational knowledge and skills of health professions students and teach them the importance of interprofessional collaboration. <b>Methods.</b> An existing interprofessional case study about a Hispanic man suffering from multiple chronic health conditions and the impact his health had on his family served as the basis for the film. To ensure a high-quality production, faculty members partnered with a local theatre company to produce the film. Upon completion, the film was integrated into an annual interprofessional forum and evaluated by both students and faculty members in 2016, 2017, and 2018. <b>Results.</b> The 22-minute film, entitled <i>Meet Fred Santiago</i>: <i>Improving Care Through Interprofessional Collaboration</i>, was shown to 1921 students and 250 faculty members who participated in the interprofessional forum over the three years. Of these, 1858 students and 174 faculty members completed a program evaluation following the forum. The majority (&gt;86%) of student and faculty respondents agreed or strongly agreed that the film presented a realistic view of the challenges faced by people with multiple chronic health problems. The majority of students (&gt;85%) agreed or strongly agreed that the film helped them appreciate the breadth of issues confronting individuals with multiple chronic health problems. <b>Conclusion.</b> The film, <i>Meet Fred Santiago</i>, is an effective tool for introducing health professions students to the complex interrelationship of medical, psychological, and social issues experienced by individuals with chronic health conditions.
Pulmonary involvement in rheumatoid arthritis
Authors: P. Cervantes-Perez
Journal: JAMA (1980)

Diffuse pulmonary affection in rheumatoid arthritis remains a controversial subject that requires further and more accurate investigation. All patients with rheumatoid arthritis attending a general hospital during a six-year period underwent clinical, radiological, and functional pulmonary evaluation and serological investigation. Twenty-five had an open lung biopsy for microscopic examination and immunofluorescence. The histopathological findings in this group were correlated with the clinical, radiological, functional, and serological alterations and with the clinical course of the rheumatoid process as well. Pulmonary affection in this series was a common finding, showing definite histopathological patterns and particular clinical features. (<i>JAMA</i>243:1715-1719, 1980)
Maternal cocaine use during early pregnancy as a risk factor for congenital urogenital anomalies
Authors: G. F. Chavez
Journal: JAMA (1989)

To study the association of maternal cocaine use during early pregnancy with the occurrence of congenital urogenital anomalies, we analyzed data from the population-based Atlanta Birth Defects Case-Control Study. We identified 276 and 791 case-babies with urinary and genital anomalies, respectively, who were live born and stillborn to residents of metropolitan Atlanta from 1968 through 1980. There were 2835 and 2973 respective control-babies born without birth defects randomly selected through birth certificates. Maternal cocaine use during early pregnancy was defined as reported use at any time from 1 month before the pregnancy began through the first 3 months of pregnancy. We found a statistically significant association of reported cocaine use with an increased risk for urinary tract defects (crude odds ratio, 4.39; 95% confidence interval, 1.12 to 17.24) and no statistically significant association with genital organ defects (odds ratio, 2.26; confidence interval, 0.67 to 7.62). The findings from this study were consistent with a previously reported association of maternal cocaine use and urinary tract anomalies in animal and clinical studies. (<i>JAMA</i>. 1989;262:795-798)
Selection of breast cancer patients for adjuvant chemotherapy. Another look at the prognostic importance of involved lymph nodes
Authors: R. A. Packaud
Journal: JAMA (1977)

To aid in the selection of breast cancer patients for adjuvant chemotherapy, 263 patients with primary breast carcinoma undergoing curative surgery at the Yale-New Haven Medical Center were examined with respect to axillary lymph node involvement and prognosis. Thirty-five percent of patients with one to three axillary nodes histologycally involved with cancer relapsed within five years, as did 61% of patients with four or more cancer-positive nodes. Equally important was the clinical stage. Stage III patients had a poor prognosis (71% relapse rate) regardless of their axillary status. Stage I patients with metastasis to one to three axillary nodes did just as well as stage I patients with no nodal involvement (13% relapse rate). Relapse rates within the nodal categories are significantly less (<i>P</i>&lt;.05) than those reported by the National Surgical Adjuvant Breast Project. (<i>JAMA</i>238:1034-1036, 1977)
HEALTH ASPECTS OF OLYMPIC GAMES
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Toxic epidermal necrolysis, azotemia, and death after allopurinol therapy
Authors: G. L. Kantor
Journal: JAMA (1970)

Shortly after initiating therapy with allopurinol, eosinophilia developed in a 72-year-old man along with toxic epidermal necrolysis and renal failure followed by sepsis, pneumonia, and death. Pathological findings revealed degeneration of the epidermis with bullae at the dermalepidermal junction and within the epidermis and also intense immunoglobulin deposits along the glomerular basement membrane.
Issue Information ‐ TOC
Journal: Allergy (2018)

About the coverIn this issue of Allergy, Torres et al. have summarized the challenges, highlighted the recent fi ndings and discussed the controversies surrounding drug hypersensi vity as discussed at the EAACI 8th Drug Hypersensi vity Mee ng (DHM) in Amsterdam.The cover fi gure depicts the mechanisms underlying ac va on of mast cells by drugs that may engage immunologic and non-immunologic processes.IgE-mediated mast cell degranula on is induced in the process known as cross-linking when covalent drug-carrier protein is recognized by two adjacent specifi c IgE molecules.Degranula on of mast cells may be also ini ated by IgG immune complex forma on or upon complement component binding to the receptor.Some drugs may be recognized by the newly iden fi ed mast cell receptor, Mas-related G-protein-coupled receptor member X2 (MRGPRX2), inducing IgE-independent degranula on.Mechanisms of mast cell activation by drugs
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Authors: Nasser H. Hanna, Andrew G. Robinson, Sarah Temin, Sherman Baker, Julie R. Brahmer, Peter M. Ellis, Laurie E. Gaspar, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, Ishmael Jaiyesimi, David H. Johnson, Natasha B. Leighl, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, Navneet Singh, David R. Spigel, Joan Tashbar, Gregory Masters
Journal: Journal of Clinical Oncology (2021)

PURPOSE To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic therapy for patients with stage IV NSCLC without driver alterations was published separately. METHODS The American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario) NSCLC Expert Panel updated recommendations based on a systematic review of randomized controlled trials (RCTs) from December 2015 to January 2020 and meeting abstracts from ASCO 2020. RESULTS This guideline update reflects changes in evidence since the previous update. Twenty-seven RCTs, 26 observational studies, and one meta-analysis provide the evidence base (total 54). Outcomes of interest included efficacy and safety. Additional literature suggested by the Expert Panel is discussed. RECOMMENDATIONS All patients with nonsquamous NSCLC should have the results of testing for potentially targetable mutations (alterations) before implementing therapy for advanced lung cancer, regardless of smoking status recommendations, when possible, following other existing high-quality testing guidelines. Most patients should receive targeted therapy for these alterations: Targeted therapies against ROS-1 fusions, BRAF V600e mutations, RET fusions, MET exon 14 skipping mutations, and NTRK fusions should be offered to patients, either as initial or second-line therapy when not given in the first-line setting. New or revised recommendations include the following: Osimertinib is the optimal first-line treatment for patients with activating epidermal growth factor receptor mutations (exon 19 deletion, exon 21 L858R, and exon 20 T790M); alectinib or brigatinib is the optimal first-line treatment for patients with anaplastic lymphoma kinase fusions. For the first time, to our knowledge, the guideline includes recommendations regarding RET, MET, and NTRK alterations. Chemotherapy is still an option at most stages. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
Lypressin Nasal Spray
Authors: Neva Mimica
Journal: JAMA (1968)

Three patients with diabetes insipidus manifested allergic reactions to various antidiuretic hormone preparations of animal origin. After using vasopressin (Pitressin) tannate in oil, one patient had an extensive skin eruption and another had marked tenesmus and constipation. The third patient had allergic rhinitis and asthma after using posterior pituitary snuff. In all three patients, the use of lypressin (lysine-8-vasopressin) led to good control of their diabetes insipidus, and its use was not attended by any allergic symptoms or other side effects.
Correction: Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial
Authors: Betina Durovni, Valeria Saraceni, Susan van den Hof, Anete Trajman, Marcelo Cordeiro-Santos, Solange Cavalcante, Alexandre Menezes, Frank Cobelens
Journal: PLoS Medicine (2015)

During a secondary analysis, the authors discovered 147 duplicate entries in their study database that consists of over 30,000 entries.The duplication of entries was randomly distributed and after reanalysis only minor changes in effect measures, which do not impact the authors' conclusions, were observed.For example, the notification rate ratio for laboratory confirmed TB (the study's primary endpoint) was 1.59 (95% CI 1.31-1.88) in the original analysis and 1.60 (95% CI 1.31-1.89) in the revised analysis.A revised version of Table 4 is presented below.
Presumed neurotrophic skeletal disease in diabetic kidney transplant recipients
Authors: R. C. Thompson
Journal: JAMA (1983)

A retrospective review of kidney transplant cases from 1969 to 1974 revealed a 20% incidence of neuropathic skeletal disease among diabetic patients, with the highest incidence occurring in the third and fourth years after transplantation. There were no identifiable differences in immunosuppressive drug management and sex predilection among nondiabetic kidney transplant recipients and the diabetic kidney transplant recipients. The presence of painless swelling in the lower extremity of these at-risk patients should be considered an early sign of impending pathological fracture, joint disruption, or both. (<i>JAMA</i>1983;249:1317-1319)
Abstract 2686: In vivo ERK1/2 pathway reporting during acquired resistance to combined RAF/MEK inhibition
Authors: Ileine Sanchez, Andrew Aplin
Journal: Cancer Research (2015)

Abstract The MEK-ERK1/2 signaling pathway is constitutively activated in BRAF V600E/K melanomas. Concurrent BRAF and MEK inhibitor treatment was recently FDA-approved for BRAF V600E melanoma; however, acquired resistance to the drug combination limits durable responses. Our lab has developed a luciferase reporter system that temporally and non-invasively quantitates ERK1/2 activity in mutant BRAF melanoma xenografts. We used this reporter system to examine the temporal kinetics of ERK1/2 activity in vivo upon treatment with combined BRAF/MEK inhibition. Using a 1205Lu reporter system, all established tumors regressed to levels that were not detectable visually. After prolonged treatment with BRAF and MEK inhibitors, only 2 out of 8 mice regrew resistant tumors. In similar experiments with A375 xenografts, only 1 out 12 tumors developed resistance. In 1205Lu tumors, re-activation of the ERK1/2 pathway was evident prior to re-growth. Additionally, cell lines generated from these resistant tumors exhibited elevated levels of ERK1/2 suggesting that resistance to BRAF + MEK inhibitors involves re-activation of ERK1/2 signaling. In comparison to parental cells, resistant cells in vitro displayed reduced levels of apoptosis, increased proliferation, and increased viability in the presence of BRAF plus MEK inhibitor. Furthermore, when removed from drugs, combination-resistant cells showed increased apoptosis and reduced proliferation and viability, suggesting that the resistant lines may be addicted to the dual therapy. RPPA analysis and whole exome sequencing to elucidate mechanisms of resistance are ongoing. Citation Format: Ileine Sanchez, Andrew Aplin. In vivo ERK1/2 pathway reporting during acquired resistance to combined RAF/MEK inhibition. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2686. doi:10.1158/1538-7445.AM2015-2686